Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - mometasone furoate -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ondansetron hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ondansetron hydrochloride, quantity: 4.98 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; water for injections; sodium citrate dihydrate - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. prevention and treatment of postoperative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; hydrogenated castor oil; colloidal anhydrous silica; maize starch - irbesartan hct medis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; citric acid monohydrate; magnesium stearate; povidone; purified talc; alginic acid; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: alginic acid; magnesium stearate; povidone; purified talc; hypromellose; citric acid monohydrate; microcrystalline cellulose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - azithromycin -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: alginic acid; citric acid monohydrate; povidone; microcrystalline cellulose; hypromellose; magnesium stearate; purified talc; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: citric acid monohydrate; microcrystalline cellulose; alginic acid; povidone; hypromellose; magnesium stearate; purified talc; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: citric acid monohydrate; povidone; alginic acid; microcrystalline cellulose; magnesium stearate; purified talc; hypromellose; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.